Answers are grounded in this paper and cite their sources.
Atopic dermatitis (AD) and inflammatory bowel disease (IBD) frequently co-occur along the gut–skin axis, yet the systemic triggers, particularly environmental endocrine-disrupting chemicals like perfluorooctanesulfonic acid (PFOS), remain poorly understood. Here, we integrate network toxicology and single-cell multi-omics to propose a computational framework for the shared molecular signatures of PFOS-driven AD and IBD comorbidity. Utilizing large-scale clinical transcriptomic cohorts and machine learning, we computationally predicted the transcription factor MYC as a potential core pathological hub. Single-cell transcriptomics and in silico virtual perturbation models revealed that aberrant MYC activation is highly restricted to barrier-forming cells: epidermal keratinocytes and intestinal mucosal progenitors. This spatially specific dysregulation not only compromises epithelial structural integrity but also reshapes local chemotactic networks, driving macrophage pro-inflammatory polarization and immune imbalance. To translate these findings, high-throughput drug repurposing screening and 200 ns all-atom molecular dynamics simulations identified the antiviral drug Elbasvir as a stable, high-affinity MYC inhibitor. Collectively, our work proposes a single-cell spatial pathology of environment-driven shared pathologies across the gut–skin axis and provides a theoretical pharmacological strategy to intervene in systemic inflammatory networks.
No takes yet. Share an insight, caveat, or question.
Du et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: